Generative Biology: The Flywheel of AI-Driven Drug Discovery
How AI is solving the protein folding problem and enabling rational design of therapeutics.
Complete Series Progress
7 parts ⢠Hover to view individual progress
â Key Takeaways
About This Series
Biology is becoming programmable. This 7-part series explores how generative AI is solving the protein folding problem (AlphaFold), enabling inverse folding (designing proteins with specified functions), and accelerating drug discovery through small-molecule design, antibody engineering, and virtual labs. Discover the flywheel effect where AI-designed therapeutics power a feedback loop of continuous improvement.
All Parts
The Language of Life (Part 1): How Generative AI Learned to Speak 'Protein'
From linguistics to biophysicsâunderstanding how Protein Language Models learn the deep grammar of biology from 200M+ sequences.
The Language of Life (Part 2): Beyond AlphaFoldâFrom 'Reading' a Fold to 'Writing' a Function
Solving the inverse folding problem with 3D diffusion models to design novel protein functions from first principles.
The Language of Life (Part 3): The 'Digital Locksmith'âGenerative AI for Small Molecule Design
Moving beyond brute-force HTS to intelligent, 3D-equivariant generation of optimized small molecule drugs.
The Language of Life (Part 4): 'Dreaming Up' AntibodiesâGenerative AI for Biologics
Co-generating binding and developability with multi-objective antibody design platforms.
The Language of Life (Part 5): The 'Virtual Lab'âHow We Validate Generative Drugs In Silico
Testing 1,000 drug candidates in one day using Digital Twin systems biology simulations and proteome-wide toxicity screening.
The Language of Life (Part 6): Closing the LoopâFrom In Silico Design to In Vitro Data
The self-driving laboratory flywheel that connects AI theory to experimental facts through active learning.
The Language of Life (Part 7): Generative Biology is HereâHow to Start Your First In Silico Design Program
Partner with the platform: Two tangible first projects to accelerate your R&D pipeline today.